UMM logo

Maryland Heart Center

Research Highlights

Selected References for Ashwani Khanna, Ph.D., Director, Cardiac Allograft Vasculopathy Research Laboratory

  1. Khanna AK and Pieper G. NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and tacrolimus-induced nephrotoxicity in a rat renal transplant model. Accepted Nephrol Dial Transplant. 2007 ; 22:376-85.

  2. Khanna AK, Mehra MR Targeted in vitro and in vivo gene transfer into T lymphocytes: potential of direct inhibition of allo-immune activation. BMC Immunol. 2006; 7:26-35.

  3. Khanna A. Reciprocal role of cyclins and cyclin kinase inhibitor p21WAF1/CIP1 on lymphocyte proliferation, allo-immune activation and inflammation. BMC-IMMUNOLOGY, 6: 22-30, 2005.

  4. Khanna A, Plummer, M, Nilakantan V, and Pieper G. p21 protein inhibits lymphocyte activation and transcription factors. J Immunology. 2005; 174: 7610-7.

  5. Khanna AK Tacrolimus and cyclosporine in vitro and in vivo induce osteopontin mRNA expression in renal tissues. Nephron Exp Nephrol. 2005; 101(4): e119-e126.

  6. Khanna AK, Plummer MS, Hilton G, Pieper GM and Ledbetter S. Anti-TGF-τ -antibody at low, but not high doses, limits CsA-mediated nephrotoxicity without altering rat cardiac allograft survival: potential of therapeutic applications. Circulation 2004 110: 3822-3829.

  7. Khanna A. Concerted effect of transforming growth factor-β, cyclin inhibitor p21, and c-myc on smooth muscle cell proliferation Am J Physiol Heart Circ Physiol 286: H1133-H1140, 2004.

  8. Khanna A. Prolongation of Skin Xenograft Survival with modified cultured fibroblasts. A discussion. Plastic and Reconstructive Surgery 111: 263-265, 2003.

  9. Khanna AK Tacrolimus induces the Expression of the Cyclin Inhibitor p21 in lymphoid and non-lymphoid cells Biochem Biophys Res Commun. 303:266-72, 2003.

  10. Pieper GM, Nilakantan V, Hilton G, Halligan NLN, Felix CC, Kampalath B, Khanna AK, Roza AM, Johnson CP, Adams MB. Mechanism of the protective action of diethyldithiocarbamate-iron complex on acute cardiac allograft rejection. Am J Physiol Heart Circ Physiol. 284:H1542-51, 2003.

  11. Khanna AK, Hosenpud JS, Plummer MS and Hosenpud JD. Analysis of TGF-β and pro-fibrogenic molecules in a rat cardiac allograft model treated with Cyclosporine. Transplantation 73: 1543-1549, 2002.

  12. Khanna AK, Plummer M, Bromberek K, Bresnahan B and Hariharan S. Expression of TGF-β and Fibrogenic Genes in Transplant Recipients with Tacrolimus and Cyclosporine Nephrotoxicity. Kidney Int. 62:2257-63, 2002.

  13. Khanna A, Plummer M, Bromberek K, Woodliff J and Hariharan S. Immuno Modulation In Stable Renal Transplant Recipients With Concomitant Tacrolimus And Sirolimus Therapy. BMC Medical Immunology, 1:3-9, 2002.

  14. Khanna A. Cell cycle control and immunosuppression in organ transplantation. Transplantation Proc. 33: 2101-2106, 2001.

  15. Khanna AK. Mechanism of the combination immunosuppressive effects of Rapamycin with either cyclosporine or tacrolimus. Transplantation 70: 690-694, 2000.

  16. Khanna A K and Hosenpud JD In vitro and in vivo transfection of p21 gene enhances Cyclosporine mediated inhibition of lymphocyte proliferation. J Immunology 165: 1882-1888, 2000.

  17. Khanna A. et al. Augmentation of the expression of proangiogenic genes in cardiomyocytes with low dose laser irradiation in vitro. Cardiovascular Radiation Medicine 1: 265-269, 1999.

  18. Khanna A, Cairns V, and Hosenpud JD. Tacrolimus induces increased expression of transforming growth factor-beta in lymphoid and non-lymphoid cells. Transplantation 67: 614-619, 1999.

  19. Khanna A, Cairns V, Becker CG and Hosenpud JD. Transforming Growth Factor-β (TGF-β) mimics and anti-TGF-β antibody abrogates the in-vivo effects of Cyclosporine: demonstration of a direct role of TGF-β in immunosuppression and nephrotoxicity of CsA. Transplantation 67: 882-889, 1999.

  20. Khanna AK and Hosenpud, JD. Cyclosporine induces the expression of the cyclin inhibitor p21. Transplantation 67: 1262-1268, 1999.

For More Information


Please call if you would like to make an appointment or talk to someone about our services. Patients dial 1-800-492-5538 or 410-328-5842, physicians dial 410-328-6622 or 1-800-318-1019.